Northland Securities Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $28
Northland Securities Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $28
Northland Securities Reaffirms Their Buy Rating on Alvotech (ALVO)
Barclays Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $18
Barclays Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $18
Barclays Sticks to Their Buy Rating for Alvotech (ALVO)
Barclays Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $18
Alvotech (ALVO) Gets a Buy From Barclays
Barclays Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $18
Alvotech's Strong Q2 Performance and Positive Outlook Justify Buy Rating
Barclays Maintains Overweight on Alvotech, Lowers Price Target to $18
Alvotech Analyst Ratings
Barclays Maintains Alvotech(ALVO.US) With Buy Rating, Cuts Target Price to $18
Alvotech Analyst Ratings
Alvotech (ALVO) Receives a Buy From Northland Securities
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Vir Biotechnology (VIR) and Alvotech (ALVO)
Analysts Are Bullish on These Healthcare Stocks: Alvotech (ALVO), Cardinal Health (CAH)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Alvotech (ALVO) and Pacific Biosciences (PACB)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
Alvotech Analyst Ratings